. In addition, we tested the response of the PEL cells to selected cytokines and the effects of neutralizing anti-cytokine and anti-cytokine receptor antibodies. Using specific ELISAs, PEL cell lines were found to produce large amounts of interleukin-6 (IL-6; 10-5000 pg/ml), IL-6 soluble receptor (IL-6sR; 30-600 pg/ml), IL-10 (600-80 000 pg/ml) and oncostatin M (OSM; 50-80 pg/ml) which in most cases were significantly higher than the levels produced by the Burkitt, B-NHL or myeloma cell lines; on the contrary, PEL cell lines did not elaborate significant levels of macrophage inhibitory protein (MIP-1␣) and leukemia inhibitory factor (LIF). However, the levels of MIP-1␣ were increased 10-to 100-fold by treatment with phorbol ester TPA. PEL cell lines did not respond proliferatively to IL-6, IL-10, IL-11, LIF, MIP-1␣, or OSM. Incubation with IL-6sR and IL-6 inhibited cell growth. Anti-IL6 neutralizing antibodies had no effect on PEL cell line proliferation; conversely, whereas anti-IL6R alone inhibited only weakly, anti-gp130 and anti-gp130 plus anti-IL6R showed strong inhibitory effects (Ͼ20% inhibition in 5/9 lines and Ͼ60% inhibition in 3/9 lines). In summary, PEL cell lines produce high amounts of cytokines (IL-6, IL-10, OSM); proliferation could be inhibited by blocking the receptors of the IL-6 signaling pathway.
Introduction
Human herpesvirus type 8 (HHV-8; also termed Kaposi's sarcoma-associated herpesvirus, KSHV) was first isolated in Kaposi's sarcoma tissue of patients with acquired immunodeficiency syndrome (AIDS).
1 HHV-8 was subsequently found in tumor cells and peripheral blood mononuclear cells from patients with primary effusion lymphomas (PEL; also termed body cavity-based lymphomas, BCBL). 2 PEL arise predominantly, but not exclusively, in human immunodeficieny virus (HIV)-positive patients and are characterized by presentation as malignant effusions without solid tumor masses (reviewed in Ref. 3) . PEL has been recognized as an individual nosologic entity based on its distinctive clinical and biological features, including immunoblastic morphology, indeterminate immunophenotype, clonal immunoglobulin receptor gene rearrangements (indicating a B cell genotype), frequent co-infection with Epstein-Barr virus (EBV), and absence of c-myc rearrangements (reviewed in Ref. 4) . However, the pathogenesis and growth control mechanisms of PEL cells are not well understood. 5 Studies on Kaposi's sarcoma-derived cell lines showed that these cells produce various cytokines and chemokines. 6, 7 Of particular interest are the findings that these cells secrete and respond to interleukin-6 (IL-6) and oncostatin M (OSM) suggesting a possible autocrine and/or paracrine growth regulation. 6, [8] [9] [10] HHV-8 infection may conceivably cause the cytokine production in these cells. 11 It is known that viral genes can transactivate cellular genes; such transactivation is thought to be one of the mechanisms of tumorigenesis. 12 Furthermore, HHV-8 has acquired a number of homologs to cellular genes. These homologs include three macrophage inflammatory protein (MIP) chemokines, IL-6, an IL-8-like receptor, an interferon regulatory factor (IRF) protein and others. 12, 13 HHV-8 vIL-6 has been shown to have biological properties similar to human IL-6.
14 EBV, which (as pointed out above) often co-infects PEL cells, contains an IL-10 homologue (BCRF-1) in its genome. 15 The results reported on Kaposi's sarcoma cell lines and the interesting molecular piracy of cytokine genes by HHV-8 led us to study the production of cytokines by PEL cells. We placed particular emphasis on production of and response to IL-6 (and other cytokines binding to components of the same receptor family such as leukemia inhibitory factor (LIF), OSM and IL-11), IL-10, and MIP-1␣. IL-6 overexpression has been implicated in a number of human malignancies, especially tumors of B cell origin; this cytokine has been found to act in a paracrine or autocrine manner to stimulate growth of multiple myeloma, acute myeloblastic leukemia, and some lymphomas. 16 Myeloma and plasmacytoma cell lines have been established which are dependent on IL-6. 17 It has recently been reported (although these data are highly controversial) that HHV-8 infects bone marrow dendritic cells of myeloma patients; the IL-6 secretion of the HHV-8+ dendritic cells is assumed to influence the myeloma cell growth. 18 Finally, IL-10 was described as autocrine growth factor for B cell lymphomas. 19 We determined the production of IL-6, IL-10, LIF, OSM, MIP-1␣ and of the soluble IL-6 receptor (IL-6sR) by PEL cells under constitutive and activated conditions; we further evaluated the proliferative response of PEL cells to IL-6, IL-6sR, IL-10, IL-11, LIF, OSM and MIP-1␣; finally, we also examined the effects of neutralizing antibodies against IL-6 and against both IL-6 receptors (IL-6R/gp80/CD126 and gp130/CD130). We used here nine different PEL cell lines as in vitro models in which the conditions are standardized and the data can be reproduced without the variability associated with primary cells.
Materials and methods

Culture of cell lines
The continuous cell lines (Table 1) were taken from the stock of the DSMZ cell bank 21 or were provided for research purposes by the original investigators. 20 The characteristics of the cell lines, information on the patient from whom they were derived, growth media and references are provided in the DSMZ catalogue 21 or are described in the literature which can be provided upon request. 22 Murine hybridoma cell line B9 (DSM ACC 211) was used in a bioassay for detection of active IL-6. Cell lines were grown at 37°C in a humidified atmosphere of air containing 5% CO 2 . The basal growth media (RPMI 1640 or Iscove's modified Dulbecco's medium; Gibco BRL, Life Technologies, Eggenstein, Germany) were supplemented with 10-20% heat-inactivated (at 56°C for 45 min) 
ELISA for cytokines
Conditioned media (CM) of the cell lines were prepared by incubating cells without or with 2 × 10 −8 M O-tetradecanoylphorbol 13-acetate (TPA; Sigma) under standard culture conditions at 0.5 × 10 6 cells/ml in 2 ml in 24-well plates in RPMI 1640 medium plus 20% FBS for 48 h. Supernatant was harvested by centrifugation to remove cells and debris; CM were aliquoted and stored at −20°C. CM were tested for IL-6, IL6sR, IL-10, LIF, MIP-1␣ and OSM by enzyme-linked immunoabsorbent assays (ELISA) purchased from R & D Systems (Wiesbaden, Germany) according to the instructions of the manufacturer. In brief, 100-200 l of standards or samples were applied into wells precoated with anti-human cytokine monoclonal antibodies (McAbs). After 2 h of incubation and thorough washing steps, 200 l of McAb against different epitopes of the cytokines conjugated with horseradish peroxidase were added and the plates were incubated for another 1-2 h at room temperature. After washing the wells, 200 l of the substrate were applied into each well. Plates were incubated at room temperature for another 20-30 min, and finally 50 l of stop solution were added to inhibit the enzymatic reaction. The OD values (450/540 nm) were determined using an automated ELISA reader (Titertek Multiskan MCC/340; Flow ICN, Meckenheim, Germany). The data are presented as a mean of two analyses tested each in duplicate at two different occasions.
Proliferation assay
The proliferative responses of PEL cell lines to cytokines, to cytokine-inhibitory and cytokine receptor-blocking McAbs and of B9 cells to PEL cell line conditioned media (CM) were examined by standard 3 H-thymidine incorporation and ␤-scintillation counting (LKB 1209 Rackbeta; Pharmacia, Freiburg, Germany). The cells were seeded in triplicate in 100 l medium in flat-bottomed 96-well plates and incubated in the absence or presence of cytokines; for the last 4 h of the 48 h incubation period, 1 Ci [methyl-
3 H]thymidine (Amersham, Braunschweig, Germany) was added to each well; PEL cells were seeded at 6.25 and 12.5 × 10 4 cells/ml in serum-free medium (SFM-Medium; Gibco BRL); B9 cells were seeded at 2.5 × 10 3 cells/ml. All 3 H-thymidine incorporation assays were performed at least twice at different occasions. The following commercially supplied cytokines and neutralizing antibodies (all from R & D) were used at the concentrations indicated: 10-100 ng/ml IL-6; 100 ng/ml IL-10; 100 ng/ml IL-11; 100 ng/ml LIF; 100 and 200 ng/ml MIP-1␣; 100 ng/ml OSM; 10-100 g/ml anti-IL6; 10-100 g/ml anti-IL-6R (gp80); 10-100 g/ml anti-gp130. Secretion of IL-6 and IL-6sR by PEL cell lines in comparison with other B lineage cell lines. Cells were seeded at 0.5 × 10 6 cells/ml; conditioned media were harvested after 48 h; IL-6 and IL6sR concentrations were examined using specific ELISAs (the lower sensitivity limit of the ELISAs was 1 pg/ml as indicated by the broken line). Shown are the results of one representative experiment; each dot represents one cell line; horizontal bars indicate the means. Note the log scale of the y-axis. The PEL cell lines clearly secreted the highest amounts of IL-6 and shed also large quantities of IL-6sR. B-NHL cell lines: for IL-6, n = 3, mean of 20 pg/ml, range 1-55 pg/ml; PEL cell lines: for IL-6, n = 9, mean of 675 pg/ml, range 12-5018 pg/ml, and for IL-6SR, n = 9, mean of 202 pg/ml, range 30-616 pg/ml; myeloma cell lines: for IL-6, n = 3, mean of 6 pg/ml, range 1-15 pg/ml, and for IL-6sR, n = 7, mean of 1350 pg/ml, range 130-5500 pg/ml.
Results
Cytokine production by PEL cell lines
Cytokine production of nine PEL cell lines was investigated by measuring the cytokine concentrations in the 48 h-conditioned media using specific ELISAs, both constitutively and after stimulation with the phorbol ester TPA. Several other continuous hematopoietic cell lines arrested also along the B cell differentiation axis were examined for comparison (Table  1) : five Burkitt, seven other B-NHL (CLL, PLL, HCL, DLCL, immunoblastic and lymphoblastic NHLs), and seven myeloma-derived cell lines. We evaluated secretion of IL-6, IL-10, MIP-1␣, LIF and OSM, and of the IL-6 soluble receptor (IL-6sR). All cell lines were seeded at 0.5 × 10 6 cells/ml and incubated under identical conditions for 48 h in order to allow for direct comparisons.
All nine PEL cell lines secreted IL-6 ranging from 10 to more than 5000 pg/ml, on average significantly more than Burkitt, other B-NHL and myeloma cell lines ( Figure 1 , Table 2 ). Similar to myeloma lines, but in contrast to Burkitt and B-NHL lines, PEL cell lines secreted also large quantities of IL-6sR ranging from about 30 to 600 pg/ml (Figure 1 ). IL-10 and MIP- cells/ml; conditioned media were harvested after 48 h; h; IL-10 and MIP-1␣ concentrations were examined using specific ELISAs (the lower sensitivity limit of the ELISAs was 1 pg/ml as indicated by the broken line). Shown are the results of one representative experiment; each dot represents one cell line; horizontal bars indicate the means. Note the log scale of the y-axis. The PEL cell lines clearly secreted the highest amounts of IL-10, but less MIP-1␣ than the other cell line types. Burkitt cell lines: for IL-10, n = 4, mean of 642 pg/ml, range 1-206 pg/ml, and for MIP-1␣, n = 5, mean of 883 pg/ml, range 60-2300 pg/ml; B-NHL cell lines: for IL-10, n = 4, mean of 90 pg/ml, range 43-150 pg/ml, and for MIP-1␣, n = 7, mean of 8633 pg/ml, range 30-46 700 pg/ml; PEL cell lines: for IL-10, n = 9, mean of 30 354 pg/ml, range 10 240-77 630 pg/ml, and for MIP-1␣, n = 9, mean of 335 pg/ml, range 10-1580 pg/ml; myeloma cell lines: for IL-10, n = 4, mean of 207 pg/ml, range 4-650 pg/ml, and for MIP-1␣, n = 6, mean of 14 587 pg/ml, range 10-100 000 pg/ml. 1␣ were found in most cell lines of the various differentiation stages with PEL cell lines elaborating 10-70 ng/ml IL-10 and 10-1500 pg/ml MIP-1␣ (Figure 2 ). The PEL cell lines clearly did not secrete any measurable amounts of LIF (the lower sensitivity limit was 1 pg/ml) and only 3/9 PEL cell lines secreted OSM (Figure 3 ).
There were no significant differences for secretion of IL-6, IL-6sR, IL-10, LIF and OSM between untreated and TPAtreated cells. However, exposure to 2 × 10 −8 m TPA led to a tremendous increase in the amounts of secreted MIP-1␣ in all Secretion of LIF and OSM by PEL cell lines in comparison with other B lineage cell lines. Cells were seeded at 0.5 × 10 6 cells/ml; conditioned media were harvested after 48 h; LIF and OSM concentrations were examined using specific ELISAs (the lower sensitivity limit of the ELISAs was 1 pg/ml as indicated by the broken line). Shown are the results of one representative experiment; each dot represents one cell line; horizontal bars indicate the means. Note the log scale of the y-axis. The PEL cell lines clearly secreted no LIF and only 3/9 secreted OSM. Burkitt cell lines: for LIF, n = 3, mean of 24 pg/ml, range 7-41 pg/ml; B-NHL cell lines: for LIF, n = 6, mean of 15 pg/ml, range 9-21 pg/ml; PEL cell lines: for OSM, n = 3, mean of 65 pg/ml, range 50-84 pg/ml; myeloma cell lines: for LIF, n = 3, mean of 8 pg/ml, range 5-14 pg/ml, and for OSM, n = 4, mean of 11 pg/ml, range 6-21 pg/ml. cell lines of all cell line types (a 10-to 100-fold increase in most cell lines) (Figure 4) .
Bioactivity of the IL-6 secreted by the PEL cell lines was examined by incubating the constitutively IL-6-dependent cell line B9 with CM collected from PEL cell line cultures. Indeed, the CM from the different PEL cell lines induced B9 proliferation, albeit to various extents, but similar to the quantities of IL-6 detected by ELISA. Sensitivity and specificity of the bioassay were documented by addition of defined quantities of recombinant human IL-6 and by inhibition of the IL-6-induced proliferation with a specific anti-IL6 neutralizing antibody ( Figure 5 ). At higher concentrations of CM (5% or 10%), the CM-induced proliferation of B9 could only be partially inhibited by anti-human IL6 McAb (inhibition by a mean of 22%, range 9-34%). Specific anti-viral IL-6 antibodies were not available.
Effects of cytokines and interleukin-6 soluble receptor on PEL cell line proliferation
IL-10, IL-11, LIF, MIP-1␣, or OSM did not have any significant proliferative effects on any of the nine PEL cell lines (also not at very low cell densities such as 0.05-0.1 × 10 6 cells/ml); the stimulation indices were always below 1.5. A representative example for these experiments is shown in Figure 6 for PEL cell line HBL-6. IL-6 could stimulate growth in one cell line, however, also only weakly (stimulation index 2-2.5 vs 0.9 to 1.5 in the other cell lines) (Figure 7 ).
Instead of enhancing 3 H-thymidine incorporation, co-incubation with IL-6sR and IL-6 inhibited cell growth in comparison with IL-6-treated or untreated cells (inhibition by 15-68%) (Figures 6 and 7) . IL-6sR alone also antagonized 3 H-thymidine uptake.
Figure 4
Phorbol ester TPA strongly increases secretion of MIP-1␣ by B lineage cell lines. Burkitt, other B-NHL, PEL and myeloma cell lines were incubated at 0.5 × 10 6 cells/ml for 48 h in the absence or presence of 2 × 10 −8 m TPA. Conditioned media of all cell lines were examined for their concentrations of MIP-1␣ by specific ELISA. In all instances, elaboration of MIP-1␣ increased dramatically. Note the log scale of the y-axis. Burkitt (n = 5): mean of 883 (± 934) pg/ml without TPA to mean of 21 296 (± 22 685) pg/ml with TPA; B-NHL (n = 7): 8633 (± 15 724) pg/ml → 44 702 (± 43 299) pg/ml; PEL (n = 9): 370 (± 449) pg/ml → 7681 (± 4912) pg/ml; myeloma (n = 7): 7595 (± 17 329) pg/ml → 30 179 (± 36 477) pg/ml.
Figure 5
Proliferative response of IL-6-dependent cell line B9 to conditioned media of PEL cell lines. Murine IL-6-dependent B9 cells were incubated with various amounts of recombinant human IL-6 or different concentrations of conditioned media (CM) of PEL cell lines for 48 h; proliferative responses of B9 were assessed by standard 3 Hthymidine incorporation. Shown are the results of one representative experiment. The specificity of the bioassay was documented by the complete blocking of the rhIL-6-or PEL CM-induced proliferation with a specific anti-IL6 McAb (used at 25 g/ml). The data show that all PEL cell lines secreted large quantities of bioactive IL-6. The broken line indicates the background thymidine incorporation of untreated B9 cells. We detected a 2.8-to 16.6-fold increase of B9 cell proliferation upon exposure to 10% CM of the nine PEL cell lines (mean 12.1 ± 3.7-fold). Experiments were performed for all PEL cell lines using 10%, 5%, 2.5%, 1% and 0.1% CM which confirm the data shown; at lower CM concentrations, the CM-induced proliferation of B9 could be blocked entirely by anti-IL6 McAb.
Figure 6
Proliferative response of HBL-6 cells to various cytokines and neutralizing antibodies. HBL-6 PEL cells were incubated with 100 ng/ml IL-6, IL-10, IL-11, LIF, OSM or MIP-1␣, with 5 g/ml IL6sR, or with 25 g/ml anti-IL6, anti-IL6R or anti-gp130 neutralizing McAbs for 48 h. Proliferation-inducing or -inhibiting effects were documented by standard 3 H-thymidine incorporation. Shown are the results of one representative experiment. Note that the cytokines IL-6, IL-10, IL-11, LIF, OSM or MIP-1␣ had only minor proliferative effects (stimulation indices 1.06-1.39). Whereas anti-IL6 and anti-IL6R were only weakly effective (inhibition by 4% and 15%, respectively), IL-6sR and anti-gp130 inhibited efficiently thymidine uptake (IL-6sR: 52% inhibition; anti-gp130: 40%; anti-IL6R + anti-gp130: 57%). The broken line indicates the background thymidine incorporation of untreated HBL-6 cells.
Figure 7
Effects of IL-6sR on proliferation of PEL cell lines. Nine PEL cell lines were incubated at 6.25 or 12.5 × 10 4 cells/ml in serumfree medium with 100 ng/ml IL-6, 5 g/ml IL-6sR or both reagents for 48 h prior to measurement of 
Effects of neutralizing antibodies on PEL cell line proliferation
Treatment with anti-IL6 did not block significantly the spontaneous proliferation of the PEL cells lines (inhibition by 0-10% only) (Figure 8) . Also, the anti-IL6R neutralizing antibody was not very effective (inhibition by 5-25%). Anti-gp130 and the combination of anti-gp130 plus anti-IL6R inhibited DNA synthesis by about 10-80%, in particular in the three PEL cell lines BCBL-1, HBL-6 and CRO-AP/5, the proliferation of which was inhibited by more than 60% (Figure 8 ). The inhibi-
Figure 8
Inhibition of PEL cell line proliferation by anti-receptor neutralizing antibodies. PEL cell lines, seeded at 6.25 or 12.5 × 10 4 cells/ml in serum-free medium, were exposed to 10 g/ml anti-IL6, anti-IL6R or anti-gp130 neutralizing antibodies for 48 h prior to measurement of 3 Hthymidine incorporation. Shown are the results of one representative experiment. Anti-IL6 did not block proliferation (inhibition by 0-7%, mean 4%); anti-IL6R alone was only weakly effective (inhibition by 8-24%, mean 14%). Anti-gp130 and the combination of anti-gp130 + anti-IL6R inhibited DNA synthesis by 9-76% (mean 33%) and 15-85% (mean 40%), respectively. Polyclonal and monoclonal anti-gp130 antibodies gave similar results. tory effects of the various neutralizing reagents were dose dependent as shown representatively for PEL cell line HBL-6 in Figure 9 . There is no correlation between secretion of OSM and sensitivity to inhibition by anti-gp130 (Table 2, Figure 8 ).
Discussion
In the present study, we detected significant production of the cytokines IL-6, IL-10 and OSM in HHV-8+ PEL cell lines; proliferation of the PEL cell lines could be inhibited by blocking the receptors of the IL-6 signaling pathway. These data confirm and greatly extend the results from earlier work. 5, 26 There is strong clinical-pathological and experimental evidence that IL-6 dysregulation may be implicated in the pathology of several neoplastic lymphoid diseases (eg in multiple myeloma) and in several HHV-8-associated disorders (eg Kaposi's sarcoma and Castleman's disease). 8, 16 The involvement of IL-6 in the HHV-8-associated diseases could be related to either human IL-6 (huIL-6) or viral IL-6 (vIL-6). On one hand, HHV-8 carries a gene encoding for vIL-6 which is strongly homologous to the huIL-6 gene; this viral protein is indeed secreted by PEL cells and is capable of preventing apoptosis of the IL-6-dependent murine and human myeloma cell lines B9 and INA-6, respectively. 14, 27, 28 In addition to its ability to maintain B9 proliferation, vIL-6 activates STAT1, STAT3 and JAK1 phosphorylation which is similar to the pattern of the JAK-STAT signal pathway activation caused by huIL-6. 12 huIL-6 and vIL-6, however, differ in their interactions with the receptors for IL-6. The IL-6 receptor system consists of two membrane proteins, a ligand-binding receptor (IL-6R = gp80/CD126) and a non-binding signal transducer (gp130/CD130), both of which belong to the hematopoietic cytokine receptor family. Binding of IL-6 to IL-6R triggers the association of IL-6R and gp130, forming a high affinity IL-6
Figure 9
Dose-response curve of HBI-6 cells to anti-receptor neutralizing antibodies. HBL-6 cells, seeded at 12.5 × 10 4 cells/ml in serumfree medium, were exposed to 10-100 g/ml anti-IL6, anti-IL6R or anti-gp130 neutralizing antibodies for 48 h prior to measurement of binding site, and gp130, in turn, transduces the signal. gp130 is also essential for signal transduction by LIF, OSM and IL-11, in addition to IL-6.
29 Whereas huIL-6 requires both the IL-6R and the gp130 protein for signal transduction, vIL-6 appears to be able to induce STAT activation by binding to gp130 alone. 30 Other more recent data suggest that both receptor chains are involved in vIL-6 binding and activity.
14 As vIL-6 did not show an antagonistic effect on hu-IL-6-induced proliferation, it is conceivable that huIL-6 and vIL6 have additive effects in their induction of proliferation and/or inhibition of apoptosis. 14 On the other hand, HHV-8 may induce production of the cellular IL-6. EBV-infected B cells have increased expression of huIL-6 and EBV+ lymphoblastoid cell lines (LCL) were described to become autocrine dependent on IL-6. 31 While EBV-infected LCL are immortalized but not tumorigenic upon heterotransplantation, the overexpression of IL-6 in LCL cells led to the generation of lymphomas in nude mice. 32 As the effects of PEL cell line-produced IL-6 could be completely inhibited by a neutralizing antibody specific for huIL-6 and as it has been previously shown that vIL-6 was only active in high concentrations (and could not be blocked by the same antibody), 14 we assume that we measured production of huIL-6 in the supernatants of the PEL cell lines. It remains to be seen whether large quantities of vIL-6 are indeed produced physiologically in vivo and whether this is clinically relevant.
14 As exogenously added IL-6 did not enhance and anti-IL6 neutralizing antibodies did not inhibit proliferation of the PEL cell lines, it is possible that the IL-6 stimulatory pathway involves intracellular (intracrine) ligand-receptor interactions. Evidence that the IL-6 signaling system is, nevertheless, involved in the proliferation of PEL cells came from our experiments in which neutralizing anti-IL6R and anti-gp130 antibodies inhibited proliferation of the PEL cell lines. Future studies could investigate the activation of gp130, eg by analyzing gp130-dependent tyrosine phosphorylation of cellular substrates such as STATs in the presence or absence of antigp130 antibodies in the cell lines that are most inhibited by anti-gp130. These kinds of data would help in further understanding the function of gp130/IL-6R in PEL cell lines.
It is noteworthy that one group has reported the possibility of growing in vitro human myeloma cells with a combination of IL-6 and the soluble receptor of IL-6 (IL-6sR), but not with IL-6 alone which was assumed to be due to a too weak membrane IL-6R expression on myeloma cells. 33 In our system using PEL cell lines that also did not respond proliferatively to exogenous IL-6, co-incubation with IL-6 and IL-6sR strongly blocked proliferation of PEL cell lines which was also seen when using IL-6sR alone.
The strong constitutive expression of IL-10 raises the question whether this reflects the biological properties of this type of lymphoma or whether IL-10 production is related to the infection with HHV-8 and/or EBV. Here, we found high IL-10 production in both EBV-negative and -positive PEL cell lines. IL-10 has been reported to act as an autocrine growth factor for various lymphoma cells; 19, 34 in our hands, PEL cell lines did not respond proliferatively to IL-10 added to the culture medium. However, the results that exposure of the PEL cell lines to externally added IL-10, IL-11, LIF and OSM failed to demonstrate any proliferative effects does not exclude any involvement of these cytokines in the growth or survival of PEL cells. In summary, we described here the expression and regulation of several cytokines in PEL cells. We provided evidence that IL-6 is associated with the growth of PEL. We used PELderived cell lines as model systems which, however, have been validated as important experimental models for the pathogenesis of this disorder. 12, 22 dell' AIDS, Roma, Italia and by 'Fondazione Piera Pietro e Giovanni Ferrero', Alba, Italia.
